The latest price target for Immunovant (NASDAQ:IMVT) was reported by HC Wainwright & Co. on September 10, 2024. The analyst firm set a price target for $51.00 expecting IMVT to rise to within 12 months (a possible 81.30% upside). 29 analyst firms have reported ratings in the last year.

The latest analyst rating for Immunovant (NASDAQ:IMVT) was provided by HC Wainwright & Co., and Immunovant reiterated their buy rating.

The last upgrade for Immunovant Inc happened on October 13, 2023 when UBS raised their price target to $55. UBS previously had a neutral for Immunovant Inc.

The last downgrade for Immunovant Inc happened on September 26, 2022 when UBS changed their price target from $7 to $5 for Immunovant Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Immunovant, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Immunovant was filed on September 10, 2024 so you should expect the next rating to be made available sometime around September 10, 2025.

While ratings are subjective and will change, the latest Immunovant (IMVT) rating was a reiterated with a price target of $51.00 to $51.00. The current price Immunovant (IMVT) is trading at is $28.13, which is out of the analyst’s predicted range.